Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Small Cell Carcinoma HELP
Based on 1,807 articles published since 2010

These are the 1807 published articles about Carcinoma, Small Cell that originated from Worldwide during 2010-2020.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Guidelines update: Post-treatment follow-up of adult head and neck squamous cell carcinoma: Screening for metastasis and metachronous esophageal and bronchial locations. 2015

Blanchard, D / Barry, B / De Raucourt, D / Choussy, O / Dessard-Diana, B / Hans, S / Lafarge, D / Anonymous2430840. ·Service d'ORL, Centre François-Baclesse, Centre de Lutte Contre le Cancer Basse-Normandie, 3, avenue Général-Harris, BP 5026, 14076 Caen, France. Electronic address: d.blanchard@baclesse.fr. · Service d'ORL, Hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France. · Service d'ORL, Centre François-Baclesse, Centre de Lutte Contre le Cancer Basse-Normandie, 3, avenue Général-Harris, BP 5026, 14076 Caen, France. · Service d'ORL, CHU de Rouen, 76031 Rouen cedex 1, France. · Service d'oncologie, Hôpital Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Service d'ORL, Hôpital Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · Service d'ORL, Centre hospitalier de Périgueux, 80, avenue Georges-Pompidou, 24000 Périgueux, France. ·Eur Ann Otorhinolaryngol Head Neck Dis · Pubmed #26297072.

ABSTRACT: OBJECTIVE: The present article is an update of the guideline of the French Society of Otorhinolaryngology and Head and Neck Surgery (SFORL) on the post-treatment follow-up of adult head and neck squamous cell carcinoma concerning screening for metastasis and metachronous esophageal and bronchial locations. METHODS: A multidisciplinary work-group was entrusted with a review of the literature on the above topic. Guidelines were drawn up, based on the articles retrieved and the work-group members' own experience. These were then reviewed by an editorial group independent of the work-group. A coordination meeting then finalized the guidelines. Guidelines were graded A, B, C or "expert opinion" according to decreasing level of evidence.

2 Guideline Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2013

Jett, James R / Schild, Steven E / Kesler, Kenneth A / Kalemkerian, Gregory P. ·Division of Oncology, National Jewish Health, Denver, CO. Electronic address: jettj@njhealth.org. · Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ. · Division of Thoracic Surgery, Indiana University, Indianapolis, IN. · Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI. ·Chest · Pubmed #23649448.

ABSTRACT: BACKGROUND: Small cell lung cancer (SCLC) is a lethal disease for which there have been only small advances in diagnosis and treatment in the past decade. Our goal was to revise the evidence-based guidelines on staging and best available treatment options. METHODS: A comprehensive literature search covering 2004 to 2011 was conducted in MEDLINE, Embase, and five Cochrane databases using SCLC terms. This was cross-checked with the authors' own literature searches and knowledge of the literature. Results were limited to research in humans and articles written in English. RESULTS: The staging classification should include both the old Veterans Administration staging classification of limited stage (LS) and extensive stage (ES), as well as the new seventh edition American Joint Committee on Cancer/International Union Against Cancer staging by TNM. The use of PET scanning is likely to improve the accuracy of staging. Surgery is indicated for carefully selected stage I SCLC. LS disease should be treated with concurrent chemoradiotherapy in patients with good performance status. Thoracic radiotherapy should be administered early in the course of treatment, preferably beginning with cycle 1 or 2 of chemotherapy. Chemotherapy should consist of four cycles of a platinum agent and etoposide. ES disease should be treated primarily with chemotherapy consisting of a platinum agent plus etoposide or irinotecan. Prophylactic cranial irradiation prolongs survival in those individuals with both LS and ES disease who achieve a complete or partial response to initial therapy. To date, no molecularly targeted therapy agent has demonstrated proven efficacy against SCLC. CONCLUSION: Evidence-based guidelines are provided for the staging and treatment of SCLC. LS-SCLC is treated with curative intent with 20% to 25% 5-year survival. ES-SCLC is initially responsive to standard treatment, but almost always relapses, with virtually no patients surviving for 5 years. Targeted therapies have no proven efficacy against SCLC.

3 Guideline [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. 2011

Goeckenjan, G / Sitter, H / Thomas, M / Branscheid, D / Flentje, M / Griesinger, F / Niederle, N / Stuschke, M / Blum, T / Deppermann, K-M / Ficker, J H / Freitag, L / Lübbe, A S / Reinhold, T / Späth-Schwalbe, E / Ukena, D / Wickert, M / Wolf, M / Andreas, S / Auberger, T / Baum, R P / Baysal, B / Beuth, J / Bickeböller, H / Böcking, A / Bohle, R M / Brüske, I / Burghuber, O / Dickgreber, N / Diederich, S / Dienemann, H / Eberhardt, W / Eggeling, S / Fink, T / Fischer, B / Franke, M / Friedel, G / Gauler, T / Gütz, S / Hautmann, H / Hellmann, A / Hellwig, D / Herth, F / Heussel, C P / Hilbe, W / Hoffmeyer, F / Horneber, M / Huber, R M / Hübner, J / Kauczor, H-U / Kirchbacher, K / Kirsten, D / Kraus, T / Lang, S M / Martens, U / Mohn-Staudner, A / Müller, K-M / Müller-Nordhorn, J / Nowak, D / Ochmann, U / Passlick, B / Petersen, I / Pirker, R / Pokrajac, B / Reck, M / Riha, S / Rübe, C / Schmittel, A / Schönfeld, N / Schütte, W / Serke, M / Stamatis, G / Steingräber, M / Steins, M / Stoelben, E / Swoboda, L / Teschler, H / Tessen, H W / Weber, M / Werner, A / Wichmann, H-E / Irlinger Wimmer, E / Witt, C / Worth, H / Anonymous4130702 / Anonymous4140702. ·Institut für Theoretische Chirurgie, Universitätsklinikum Marburg, Germany. GGoeckenjan@t-online.de ·Pneumologie · Pubmed #21830177.

ABSTRACT: -- No abstract --

4 Guideline Guidelines on the radical management of patients with lung cancer. 2010

Lim, Eric / Baldwin, David / Beckles, Michael / Duffy, John / Entwisle, James / Faivre-Finn, Corinne / Kerr, Keith / Macfie, Alistair / McGuigan, Jim / Padley, Simon / Popat, Sanjay / Screaton, Nicholas / Snee, Michael / Waller, David / Warburton, Chris / Win, Thida / Anonymous19440674 / Anonymous19450674. ·Academic Division of Thoracic Surgery, Royal Brompton Hospital, London, UK. e.lim@rbht.nhs.uk ·Thorax · Pubmed #20940263.

ABSTRACT: A joint initiative by the British Thoracic Society and the Society for Cardiothoracic Surgery in Great Britain and Ireland was undertaken to update the 2001 guidelines for the selection and assessment of patients with lung cancer who can potentially be managed by radical treatment.

5 Editorial High-risk HPV and neuroendocrine carcinomas of the head and neck. 2019

Faquin, William C. ·Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. ·Cancer Cytopathol · Pubmed #30661306.

ABSTRACT: -- No abstract --

6 Editorial Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them? 2018

Gazdar, Adi F. ·Hamon Center for Therapeutic Oncology Research and Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: adi.gazdar@utsouthwestern.edu. ·J Thorac Oncol · Pubmed #29425612.

ABSTRACT: -- No abstract --

7 Editorial Pulmonary neuroendocrine carcinomas-evidence for a spectrum of differentiation. 2018

Weissferdt, Annikka. ·Department of Pathology, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. aweissferdt@mdanderson.org. ·Virchows Arch · Pubmed #29388011.

ABSTRACT: -- No abstract --

8 Editorial Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma. 2017

Farago, Anna F / Piotrowska, Zofia / Sequist, Lecia V. ·Anna F. Farago, Zofia Piotrowska, and Lecia V. Sequist, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA. ·J Clin Oncol · Pubmed #28692381.

ABSTRACT: -- No abstract --

9 Editorial Prophylactic Cranial Irradiation or No Prophylactic Cranial Irradiation after Adjuvant Chemotherapy in Resected Small Cell Lung Cancer? 2017

Le Pechoux, Cecile. ·Department of Radiation Oncology, Gustave Roussy, Villejuif, France. Electronic address: cecile.lepechoux@gustaveroussy.fr. ·J Thorac Oncol · Pubmed #28115108.

ABSTRACT: -- No abstract --

10 Editorial Evolving Treatment Options for Lung Cancer. 2017

Morgensztern, Daniel / Herbst, Roy S. ·Thoracic Oncology Program, Washington University, 660 South Euclid Avenue, Box 8056, St Louis, MO 63110, USA. Electronic address: dmorgens@wustl.edu. · Yale School of Medicine, Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT 06519, USA. Electronic address: Roy.herbst@yale.edu. ·Hematol Oncol Clin North Am · Pubmed #27912837.

ABSTRACT: -- No abstract --

11 Editorial Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma. 2017

Feng, Ninghan / Yin, Yu / He, Yiping / Huang, Jiaoti. ·Department of Urology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi, China; Wuxi Medical School, Jiangnan University, Wuxi, China. · Department of Pathology, Anhui Medical University, Hefei, China; Department of Pathology, Duke University School of Medicine, Durham, NC, USA. · Department of Pathology, Duke University School of Medicine, Durham, NC, USA. · Department of Pathology, Duke University School of Medicine, Durham, NC, USA. Electronic address: jiaoti.huang@duke.edu. ·Eur Urol · Pubmed #27481176.

ABSTRACT: -- No abstract --

12 Editorial Using a Population-Based Analysis to Determine the Management and Treatment of Early-Stage Small-Cell Lung Cancer. 2016

Pietanza, M Catherine. ·Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY cathy.pietanza@gmail.com. ·J Clin Oncol · Pubmed #26884572.

ABSTRACT: -- No abstract --

13 Editorial Sonic Hedgehog in SCLC. 2015

Laukkanen, Mikko O / Gutkind, J Silvio / Castellone, Maria Domenica. ·IRCCS SDN, Naples 80143, Italy. · Department of Pharmacology, UC San Diego Moores Cancer Center, La Jolla, CA 92093, USA. · Istituto di Endocrinologia ed Oncologia Sperimentale "G. Salvatore" (IEOS), C.N.R. 80131- Naples; Italy. ·Aging (Albany NY) · Pubmed #26420823.

ABSTRACT: -- No abstract --

14 Editorial Differentiating infantile tumors with diffusion imaging. 2015

Krieger, Mark D. ·Division of Neurosurgery, Children's Hospital of Los Angeles, California. ·J Neurosurg Pediatr · Pubmed #25955810.

ABSTRACT: -- No abstract --

15 Editorial Response. 2015

Shahar, Tal / Rozovski, Uri / Ram, Zvi. · ·J Neurosurg · Pubmed #25763428.

ABSTRACT: -- No abstract --

16 Editorial Errors in the pathology laboratory. 2015

Lopes, M Beatriz S. ·Department of Pathology (Neuropathology), University of Virginia School of Medicine, Charlottesville, Virginia. ·J Neurosurg · Pubmed #25423273.

ABSTRACT: -- No abstract --

17 Editorial The benefit of chemotherapy in elderly patients with small cell lung cancer. 2014

Caprario, Laura C / Strauss, Gary M. ·Holy Family Hospital, Cancer Management Center, 70 East Street, Methuen, MA 01844, USA. ·Expert Rev Anticancer Ther · Pubmed #24655123.

ABSTRACT: Elderly patients with small cell lung cancer derive a statistically significant benefit from the administration of combination chemotherapy. Numerous clinical trials have demonstrated high response rates and impressive median survivals with carboplatin and etoposide, cisplatin and etoposide, and other regimens. All elderly patients with small cell lung cancer should be evaluated by a medical oncologist to determine whether they are candidates for chemotherapy.

18 Editorial Molecular markers as therapeutic targets in lung cancer. 2013

Tseng, Hsin-Hui / He, Biao. ·Thoracic Oncology Program. Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA. ·Chin J Cancer · Pubmed #23369726.

ABSTRACT: Lung cancer is responsible for 29% of cancer deaths in the United States and has very low 5-year survival rates of approximately 11% in men and 15% in women. Although the early diagnosis of lung cancer may increase the survival rate with adequate treatment, advanced lung cancers are often metastasized and receive limited benefit from therapeutic regimens. As conventional treatments for lung cancer reach their limitations, researchers have attempted to discover novel drug therapies aimed at specific targets contributing to the progression of tumorigenesis. Recent advances in systems biology have enabled the molecular biology of lung carcinogenesis to be elucidated. Our understanding of the physiologic processes of tumor development provide a means to design more effective and specific drugs with less toxicity, thereby accelerating the delivery of new drug therapies to the patient's bedside.

19 Editorial Response: a critique of the international association for the study of lung cancer lymph node map. 2012

Rusch, Valerie W / Asamura, Hisao. · ·J Thorac Oncol · Pubmed #22334009.

ABSTRACT: -- No abstract --

20 Editorial A critique of the international association for the study of lung cancer lymph node map: a radiation oncology perspective. 2012

Pitson, Graham / Lynch, Rod / Claude, Line / Sarrut, David. · ·J Thorac Oncol · Pubmed #22334008.

ABSTRACT: -- No abstract --

21 Editorial Can Carboplatin replace Cisplatin in small cell lung cancer? 2011

Noronha, V. · ·Indian J Cancer · Pubmed #22293259.

ABSTRACT: -- No abstract --

22 Editorial Radiotherapy with curative intent for lung cancer: a continuing success story. 2011

De Ruysscher, Dirk / van Elmpt, Wouter / Lambin, Philippe. · ·Radiother Oncol · Pubmed #22079528.

ABSTRACT: -- No abstract --

23 Editorial Neuroendocrine carcinomas of the larynx: what do the different histologic types really mean? 2010

Devaney, Kenneth O / Ferlito, Alfio / Rinaldo, Alessandra. · ·Eur Arch Otorhinolaryngol · Pubmed #20589504.

ABSTRACT: -- No abstract --

24 Review Primary small cell carcinoma of the esophagus: progression in the last decade. 2020

Ji, Anqi / Jin, Runsen / Zhang, Renquan / Li, Hecheng. ·Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. · Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China. ·Ann Transl Med · Pubmed #32395546.

ABSTRACT: Primary small cell carcinoma of the esophagus (PSCCE) is a highly malignant tumor that is diagnosed by endoscopic biopsy and immunohistochemistry. Because of its low incidence, a high degree of malignancy, and rapid progress, it is difficult to conduct large, randomized controlled trials and to establish a standard treatment plan for this disease. In recent years, several retrospective studies have been reported, and with the rise of emerging therapies, PSCCE has gradually become a focus of thoracic surgery. This paper reviews progress in the diagnosis and treatment of PSCCE in recent years.

25 Review Pulmonary small cell carcinoma: Review, common and uncommon differentials, genomics and management. 2020

Sung, Simon / Shirazi, Maryam / Shu, Catherine A / Crapanzano, John P / Saqi, Anjali. ·Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, USA. · Feinberg School of Medicine, Northwestern Medicine, Chicago, Illinois, USA. · Columbia University Medical Center, Department of Medicine, Hematology & Oncology, New York, New York, USA. ·Diagn Cytopathol · Pubmed #32348027.

ABSTRACT: Lung cancer is the leading cause of cancer-related death worldwide. It is divided into sub-categories based upon morphology, immunostaining pattern, biology, molecular profile, and/or treatment options. Up until the early 2000s when driver mutations with targeted therapies were identified in a subset of adenocarcinomas, the most critical distinction of lung carcinomas was driven by differences in treatment between small cell carcinoma (SCC) and nonsmall cell lung carcinoma (NSCLC). The distinction between SCC and NSCLC remains critical in the 21st century for management, especially for advanced stage cancer. In the vast majority of cases, morphological features are sufficient to separate SCC from other types of lung cancers. In some instances, however, cytomorphological features and immunohistochemical overlap with other tumors, limited sample availability, and/or crush artifact pose diagnostic challenges. The aim of this review is to highlight salient features of SCC and ancillary studies to distinguish it from common and uncommon potential mimickers, as well as provide updates in genomics and management.